US Patent

US7973031 — Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity

Method of Use · Assigned to Novartis AG · Expires 2028-10-09 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of staurosporine derivatives to treat diseases involving deregulated FLT3 receptor tyrosine kinase activity, such as leukemias and myelodysplastic syndromes.

USPTO Abstract

The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.

Drugs covered by this patent

Rydapt (MIDOSTAURIN) · Novartis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2007`	—	Rydapt

Patent Metadata

Patent number: US7973031
Jurisdiction: US
Classification: Method of Use
Expires: 2028-10-09
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.